NCT01395810 - Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 15, 2012

Primary Completion Date

March 30, 2014

Study Completion Date

March 30, 2014

Conditions

Congenital Bleeding DisorderHaemophilia B

Interventions

DRUG

nonacog beta pegol

One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience.

DRUG

nonacog beta pegol

One single dose administered intravenously (into the vein). Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode.

DRUG

nonacog beta pegol

One single dose administered intravenously (into the vein) every second week. Patients will receive instruction on how to treat any bleeding episode they may experience.

Trial Locations (49)

100

Novo Nordisk Investigational Site, Taipei

1000

Novo Nordisk Investigational Site, Skopje

1090

Novo Nordisk Investigational Site, Vienna

2193

Novo Nordisk Investigational Site, Parktown Johannesburg

10029

Novo Nordisk Investigational Site, New York

10400

Novo Nordisk Investigational Site, Bangkok

13210

Novo Nordisk Investigational Site, Syracuse

20007

Novo Nordisk Investigational Site, Washington D.C.

20124

Novo Nordisk Investigational Site, Milan

21287

Novo Nordisk Investigational Site, Baltimore

28046

Novo Nordisk Investigational Site, Madrid

30625

Novo Nordisk Investigational Site, Hanover

30912

Novo Nordisk Investigational Site, Augusta

32207

Novo Nordisk Investigational Site, Jacksonville

35392

Novo Nordisk Investigational Site, Giessen

38010

Novo Nordisk Investigational Site, Kayseri

42090

Novo Nordisk Investigational Site, Konya

46026

Novo Nordisk Investigational Site, Valencia

47051

Novo Nordisk Investigational Site, Duisburg

50134

Novo Nordisk Investigational Site, Florence

50400

Novo Nordisk Investigational Site, Kuala Lumpur

52242

Novo Nordisk Investigational Site, Iowa City

53127

Novo Nordisk Investigational Site, Bonn

55404

Novo Nordisk Investigational Site, Minneapolis

69677

Novo Nordisk Investigational Site, Bron

77030

Novo Nordisk Investigational Site, Houston

94143

Novo Nordisk Investigational Site, San Francisco

94270

Novo Nordisk Investigational Site, Le Kremlin-Bicêtre

105077

Novo Nordisk Investigational Site, Moscow

191119

Novo Nordisk Investigational Site, Saint Petersburg

300011

Novo Nordisk Investigational Site, Timișoara

90027-6016

Novo Nordisk Investigational Site, Los Angeles

68198-5456

Novo Nordisk Investigational Site, Omaha

07102

Novo Nordisk Investigational Site, Newark

GR-11527

Novo Nordisk Investigational Site, Athens

634 8522

Novo Nordisk Investigational Site, Kashihara-shi, Nara

216-8511

Novo Nordisk Investigational Site, Kawasaki-shi, Kanagawa

466 8560

Novo Nordisk Investigational Site, Nagoya-shi, Aichi

663 8051

Novo Nordisk Investigational Site, Nishinomiya-shi

160 0023

Novo Nordisk Investigational Site, Shinjuku-ku, Tokyo

167 0035

Novo Nordisk Investigational Site, Suginami-ku, Tokyo

3584 CX

Novo Nordisk Investigational Site, Utrecht

06500

Novo Nordisk Investigational Site, Ankara

RG24 9NA

Novo Nordisk Investigational Site, Basingstoke

CF14 4XW

Novo Nordisk Investigational Site, Cardiff

NW3 2QG

Novo Nordisk Investigational Site, London

SE1 7EH

Novo Nordisk Investigational Site, London

M13 9WL

Novo Nordisk Investigational Site, Manchester

OX3 7LJ

Novo Nordisk Investigational Site, Oxford